Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who are male, or female and neither pregnant nor breastfeeding
• People whose major organs (such as liver, kidneys, and bone marrow) are functioning adequately
• People who had previous cancer treatments (such as chemotherapy, biological therapy, hormone therapy, PARP inhibitors, or other oral or experimental drugs) where the last dose was received at least 4 weeks (or 6 weeks for certain specific drugs) or 5 half-lives before the trial starts — whichever comes first
• People whose side effects from previous cancer treatment, radiation, or surgery have mostly resolved to a mild level or better
• People with cancer that has spread to the brain, where that brain disease has been stable after radiation treatment
• People who had extensive radiation therapy (covering 30% or more of the bone marrow) must have finished that radiation at least 28 days before the trial starts; people who had more limited palliative radiation must have finished at least 14 days before
• People whose cancer can be measured on scans using standard criteria (RECIST v1.1), with scans taken within 4 weeks before the trial starts
• People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning fully active or able to carry out light activity (confirm with trial site)
• People whose doctors estimate they have a life expectancy of more than 12 weeks
• People who are willing and able to understand and sign an informed consent form
• Women who could potentially become pregnant and are sexually active with a non-sterilised male partner must be willing to use at least one highly effective form of contraception from screening until 5 half-lives plus 6 months after the last dose of the study drug, and must agree not to donate eggs or breastfeed during this period
• Male participants who are sexually active with a female partner who could potentially become pregnant must use an effective barrier contraceptive throughout treatment and until 5 half-lives plus 6 months after the last dose, and their partner should also use a highly effective method at the same time; male participants must also agree not to donate sperm for 6 months after the last dose

Who may not be able to join:

• No specific exclusion criteria were listed in the source information provided (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.